7 February 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Concept of value-based healthcare
18 February 2020 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Methods of payment to care providers constitute an essential part of the healthcare financing system; these mechanisms determine the motivation of service providers. Throughout the history of public health care, the payment methods have been gradually improved so to stimulate the providers to best match the societal demands (greater access to health services, cost reduction, and better quality) and prevent “moral hazards”. As a result, the most advanced healthcare systems have stopped paying simply for service volume and rigorously restraining the costs. Instead, the updated system is based on the integrated payments combining the elements of cost control with the stimuli that promote a high quality and better access to healthcare service. At present, the new payment mechanisms aiming at improving the long-term treatment outcomes (life expectancy and quality of life) are available. The care provider payment system existing in Russia, by large, corresponds to the best international practices as far as the hospital care is concerned. However, the payment arrangements in the primary care network still lag behind the international standards. To improve the situation, quality indicators should be included in payments for primary care services.
9 June 2020 in Voprosy Ekonomiki
Pandemic, caused by the SARS-CoV-2 coronavirus, has resulted in economic slowdown all over the world, and in Russia too. This may require midand longterm adjustments in some policy areas, including health and demography. In current circumstances a number of measures could be implemented to improve anti-epidemic service in Russia: development and introduction of mobile application for anonymous social contacts tracking, introduction of mobile testing facilities, embedding household assistance for people that are required to isolate themselves, using hotels as hospitals for treating people with no or mild symptoms, planning investment in inpatient care facilities with respect to their possible reprofiling. Development of telemedicine technologies based on a model “physician—patient” is a useful measure for health policy. It is also possible to stimulate population’s demand by introducing governmental drug reimbursement program and earmarked grants on healthy food to people in need. Support for medical organizations is possible with calculating prices for medical services with respect to modern clinical guidelines. Finally, in order to protect patients’ rights, authority and responsibility of health insurance companies could be increased in a number of regional pilot projects. Introduction of these measures would help achieve national goals that were set by the presidential decree No. 204 from May 07, 2018.
30 June 2023 in Voprosy onkologii
Since 2019, the Federal project “Cancer control” is being implemented in Russia. The main goal of the Federal project is to reduce mortality from malignant neoplasms by 2024. The aim of the study is to assess impact of using novel antineoplastic drugs on the key performance indicators of the Federal Project. Materials and methods. We used previously described methodology to assess impact of expanding use of osimertinib (in first line locally advanced or metastatic EGFRm+ NSCLC) and durvalumab (in maintenance therapy of unresectable locally advanced NSCLC after CRT and advanced SCLC in first line) on mortality from malignant neoplasms and one-year mortality rates. Data from foreign clinical trials and real-world evidence studies were used to model overall survival of patients treated with the considered treatment options. Results. Durvalumab and osimertinib could be additionally indicated for 4 053 and 1 596 patients annually in Russia. If all of them are treated with the considered drugs, mortality rate from neoplasms could be reduced by 1 682 cases over three years (508 cases in 2023, 644 cases in 2024, and 531 cases in 2025). Increased use of osimertinib and durvalumab in late-stage lung cancer could reduce one-year mortality from malignant neoplasms by 0.11 percentage points and among lung cancer patients by 1.18 percentage points. Conclusions. Using novel antineoplastic drugs for lung cancer treatment in different clinical situations leads to quantitate reduction in cancer mortality in Russia. С 2019 г. в Российской Федерации реализуется Федеральный проект «Борьба с онкологическими заболеваниями», основная цель которого – снижение смертности населения от злокачественных новообразований (ЗНО) к 2024 году. Целью исследования является оценка эффектов от расширения применения современных лекарственных препаратов для лечения рака легкого на ключевые показатели Федерального проекта по борьбе с онкозаболеваниями. Материалы и методы. На основе представленной ранее методики оценивались эффекты от расширения практики применения осимертиниба (в первой линии местнораспространенного или метастатического EGFRm+ НМРЛ) и дурвалумаба (в консолидирующей терапии нерезектабельного местнораспространенного НМРЛ после ХЛТ и в первой линии распространенного МРЛ) на показатели смертности и одногодичной летальности. При моделировании общей выживаемости когорт пациентов, получающих варианты сравнения, использовались данные зарубежных клинических исследований и исследований реальной практики применения препаратов. Результаты. Лечение дурвалумабом и осимертинибом по рассматриваемым показаниям в России дополнительно показано 4 053 и 1 596 пациентам ежегодно. Если все они станут получать данные лекарственные препараты смертность от новообразований может быть снижена на 1 682 случая за три года (508 случаев в 2023 году, 644 случая в 2024 году и 531 случай в 2025 году). Расширение практики применения осимертиниба и дурвалумаба в поздних стадиях рака легкого способно снизить одногодичную летальность от всех ЗНО на 0,11 процентных пункта, а среди больных раком легкого – на 1,18 процентных пункта. Выводы. Применение современных противоопухолевых препаратов для лечения рака легкого в разных клинических ситуациях ведет к количественно измеримому вкладу в снижение смертности от ЗНО в России.
8 October 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
The article presents a review of current and alternative methods for planning the scope and financing of medical care in the subjects of the Russian Federation. The relevance of the issue is due to the imperfection of the current planning model, which stimulate representatives of the profile bodies and independent experts to develop alternative methods. The current approaches and legal documents regulating the procedure for distributing the scope of medical care and financial resources to pay for this care are discribed. The analysis of alternative methods shows how different demographic and infrastructural features of regions can be used to redistribute the scope of medical care and the corresponding financial support.
17 May 2024 in Tumors of female reproductive system
At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been conducted.Aim of the work is to gather and analyze published data on the comparative effectiveness of CDK4/6 inhibitors in combination with aromatase inhibitors in postmenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer. A systematic review of publications presenting results from original studies on the impact of CDK4/6 inhibitor therapy in combination with aromatase inhibitors on the survival of patients was performed. Nineteen studies with original data on progression-free survival and overall survival were identified. None of the studies found significant differences between different CDK4/6 inhibitors and aromatase inhibitors in terms of progression-free survival. A statistically significant superiority of ribociclib over palbociclib in terms of overall survival was observed in a single matching-adjusted indirect comparison, while seven other studies of various types (real-world data studies, matching-adjusted indirect comparisons, and meta-analyses) did not find significant differences between the investigated drugs in terms of overall survival.Currently, there is no compelling evidence of the superiority of one CDK4/6 inhibitor over others. The decision on the preference for a specific drug within the class can only be made after conducting direct randomized comparison trials, or accumulating sufficient real-world data on the use of palbociclib, ribociclib, and abemaciclib.